Clarity’s theranostic prostate cancer trial advances to multi-dose phase
Sydney, Australia 15 March 2024 Highlights Cohort 3 of the theranostic SECuRE trial investigating 64Cu/67Cu-SAR-bisPSMA in metastatic castrate-resistant prostate cancer (mCRPC) has been completed in 6 participants who received therapy with 67Cu-SAR-bisPSMA at the highest single dose level of 12GBq. No dose limiting toxicities (DLTs) have been reported in cohort 3 to date. An overall…